Martin Davies

Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

Yoshinobu Nakamaru, Yoshiharu Hayashi, Ruriko Ikegawa et al. · Xenobiotica · 2013 · 56 citations

Medicine, Pharmacokinetics, Pharmacology +12

A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn’s Disease

Geert D’Haens, Silvio Danese, Martin Davies et al. · Journal of Crohn s and Colitis · 2021 · 35 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

Ludwig Kappos, Douglas L. Arnold, Amit Bar‐Or et al. · Multiple Sclerosis Journal · 2017 · 33 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Effect of Ketoconazole on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: An Open-Label Study in Healthy White Subjects in Germany

Yoshinobu Nakamaru, Yoshiharu Hayashi, Mana Sekine et al. · Clinical Therapeutics · 2014 · 13 citations

Pharmacy, Pharmacokinetics, Pharmacology +7

Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults

Yoshinobu Nakamaru, Yoshiharu Hayashi, Martin Davies et al. · Clinical Therapeutics · 2015 · 12 citations

Pharmacy, Pharmacokinetics, Pharmacology +11